INVO Bioscience

IINVO BioScience, Inc. is a fertility company. It focuses on the creation of treatment options for patients diagnosed with infertility. It offers a patented medical device that is used for infertility treatment under the name INVOcell. The company was founded by Kathleen Karloff and Claude Ranoux on January 5, 2007 and is headquartered in Sarasota, FL.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NAYA Biosciences, Inc. operates a revenue-generating fertility business. It also focuses on the development of class clinical-stage assets in oncology and autoimmune diseases. The company was founded on October 14, 2024 and is headquartered in Sarasota, FL.

-     The multi-billion-dollar global fertility market is predicted to reach approximately US$47.9 billion by 2030, yet remains severely underserved with many patients (upwards of 90% by many estimates) unable to access affordable treatment. -     The INVOcell solution provides an advanced, effective and affordable infertility treatment to help increase access to care.

INVO Bioscience Highlights INVOcell Progress From the 2022 American Society for Reproductive Medicine (ASRM) Congress & Expo

SARASOTA, Fla. , Oct. 21, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell ® medical device and the intravaginal culture ("IVC") procedure it enables, today announced the publication of a review discussing existing literature and current use of intravaginal culture (IVC) as an option for patients seeking fertility therapies.

INVOcell Review Published in Current Opinion in Obstetrics and Gynecology

INVO Bioscience to Exhibit at the 2022 American Society for Reproductive Medicine (ASRM) Congress & Expo

Invo BioScience Inc. (INVO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Invo BioScience Inc. (INVO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Dr. Sue Ellen Carpenter of INVO Bioscience's Atlanta-based INVO Center - Bloom Fertility - Named Top Doctor by Castle Connolly

Invo BioScience Inc. (INVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Invo BioScience Inc. (INVO) Upgraded to Buy: Here's What You Should Know

SARASOTA, Fla. , Aug. 25, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell ® medical device and the intravaginal culture ("IVC") procedure it enables, today announced that Advanced Reproductive Centre, Hospital Canselor Tuanku Muhriz (HCTM), formally known as Hospital Universiti Kebangsaan Malaysia (HUKM), based in Kuala Lumpur, Malaysia, is making IVC available for their patients.

INVOcell Launched in Malaysia by Advanced Reproductive Centre, Hospital Canselor Tuanku Muhriz

INVO Bioscience, Inc. (NASDAQ:INVO ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Robert Blum – Investor Relations Steve Shum – Chief Executive Officer Mike Campbell – Chief Operating Officer and Vice President of Business Development Andrea Goren – Chief Financial Officer Conference Call Participants John Heerdink – Vista Partners LLC Curtis Thom – Paulson Operator Good day, and welcome to the INVO Bioscience's Reports Second Quarter 2022 Financial Results Call. All participants will be in listen-only mode.

INVO Bioscience, Inc's (INVO) CEO Steve Shum on Q2 2022 Results - Earnings Call Transcript

Company to Host Conference Call Today at 4:30pm ET SARASOTA, Fla. , Aug. 15, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced financial results for the second quarter ended June 30, 2022 and provided a business update.

INVO Bioscience Reports Second Quarter 2022 Financial Results

Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla. , Aug. 4, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the IVC procedure it enables, will report financial results for its second quarter 2022, ended June 30, 2022, after the market close on Monday, August 15, 2022.

INVO Bioscience to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022

Mark Your Calendars for July 7, 2022, with Dr. Sue Ellen Carpenter of Atlanta-based Bloom Fertility SARASOTA, Fla. , July 7, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced that Dr. Sue Ellen Carpenter of Bloom Fertility, an INVO Center in Atlanta, will be hosting "Get to Know INVOcell" - a Facebook Live Event on July 7, 2022 at 7 PM ET.

INVO Bioscience Announces "Get to Know INVOcell" - a Series of Facebook Live Events Supporting Access to Affordable Fertility Treatment

INVO Bioscience, Inc. (NASDAQ:INVO ) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Robert Blum - Lytham Partners, LLC, IR Steven Shum - CEO Michael Campbell - COO and VP, Business Development Andrea Goren - CFO Conference Call Participants John Heerdink - Vista Partners Operator Good day, and welcome to the INVO Bioscience First Quarter 2022 Financial Results Conference Call. Today all participants will be in a listen-only mode.

INVO Bioscience, Inc. (INVO) CEO Steven Shum on Q1 2022 Results - Earnings Call Transcript

Agreement includes minimum purchase obligations upon product registration and approval SARASOTA, Fla. , May 16, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced it has entered an exclusive distribution agreement with Onesky Holdings Limited ("Onesky") for Mainland China (excludes Hong Kong, Macau and Taiwan).

INVO Signs Distribution Agreement with Onesky Holding Limited for Mainland China

Company to Host Conference Call Today at 4:30pm ET SARASOTA, Fla., May 16, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced financial results for the first quarter ended March 31, 2022 and provided a business update.

INVO Bioscience Reports First Quarter 2022 Financial Results

Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla. , May 9, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the IVC procedure it enables, will report financial results for its first quarter 2022, ended March 31, 2022, after the market close on Monday, May 16, 2022.

INVO Bioscience to Report First Quarter 2022 Financial Results on Monday, May 16, 2022

Bloom Fertility, an INVO Center to grant three eligible patients a full IVC treatment cycle SARASOTA, Fla. , April 28, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced that in celebration of this year's National Infertility Awareness Week ("NIAW"), three eligible patients will be granted a full IVC treatment cycle free of charge.

INVO Celebrates National Infertility Awareness Week at the INVO Center in Atlanta, Georgia

U.S. Market Expansion Continues as Planned SARASOTA, Fla. , April 14, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced plans to open an INVO Center in Kansas City, Missouri.

INVO Selects Kansas City as additional INVO Center Location

SARASOTA, Fla. , April 4, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, announced today that it will be participating in the Lytham Partners Spring 2022 Investor Conference taking place virtually on April 4-7, 2022.

INVO Bioscience to Participate in the Lytham Partners Spring 2022 Investor Conference

INVO Bioscience, Inc. (INVO) CEO Steven Shum on Q4 2021 Results - Earnings Call Transcript

Company to Host Conference Call Today at 4:30pm ET; Slide Presentation Also Available SARASOTA, Fla. , March 31, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced financial results for the year ended December 31, 2021, and provided a business update.

INVO Bioscience Reports 2021 Financial Results

Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla. , March 24, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the IVC procedure it enables, will report financial results for its fourth quarter and fiscal year 2021, ended December 31, 2021, after the market close on Thursday, March 31, 2022.

INVO Bioscience to Report Fourth Quarter and Fiscal Year 2021 Financial Results on Thursday, March 31, 2022

SARASOTA, Fla. , March 24, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), developers of the INVOcell®, an advanced fertility treatment technology which is currently available, is exhibiting the INVOcell solution at the 2022 Pacific Coast Reproductive Society (PCRS) Annual Meeting, taking place March 23-27 at the Renaissance Esmeralda Resort & Spa in Indian Wells, CA.

INVO Bioscience to Exhibit at the 2022 Pacific Coast Reproductive Society (PCRS) Annual Meeting

SARASOTA, Fla. , March 22, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the IVC procedure it enables, announced today that Inger Britt Carlsson, PhD, INVO Bioscience's Vice President of Medical Affairs, will participate in a roundtable discussion at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest.

INVO Bioscience to Participate in Roundtable Discussion at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

SARASOTA, Fla., March 10, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), developers of the INVOcell®, an advanced fertility treatment technology which is currently available through a number of channels, including its new joint-venture owned INVO Center in Birmingham, Alabama, highlights an initiative to continuously provide transparent and affordable advanced fertility treatment solutions to combat rising patient costs.

News for INVO Bioscience Stock (INVO)